Chromos to Acquire Targeted Molecules for 20.1 Million Shares

Chromos Molecular Systems Inc. said it has signed a letter of intent to acquire Targeted Molecules Corp., a privately held San Diego biotechnology company, for 20.1 million Chromos shares equivalent to almost half of the company. The acquisition of Targeted Molecules, whose antibody product candidates are aimed at multiple sclerosis and acute thrombosis, will shift the focus of the Canadian company to monoclonal antibody products from cell therapy.

()a href="http://cnews.canoe.ca/CNEWS/TechNews/TechInvestor/2005/05/25/1055929-cp.html" target="_blank">Canoe Cnews